Drug Profile
Research programme: protozoan infection and tuberculosis therapeutics - Broad Institute/Eisai Co Ltd
Alternative Names: Chagas disease therapeutics - Broad Institute/Eisai; Malaria therapeutics - Broad Institute/Eisai; Protein synthesis inhibitors - Broad Institute/EisaiLatest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Broad Institute; Eisai Co Ltd
- Class Antimalarials; Antiprotozoals; Antituberculars; Small molecules
- Mechanism of Action Amino acyl tRNA synthetase inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chagas disease; Malaria; Protozoan infections; Tuberculosis
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Malaria in USA (PO)
- 28 Jul 2018 No recent reports of development identified for research development in Chagas'-disease in USA
- 28 Jul 2018 No recent reports of development identified for research development in Protozoal-infections in USA